Skip to content
Screener

uniQure QURE Liability From Royalty Financing Agreement Non Current

Liability From Royalty Financing Agreement Non Current at other companies

PVL
Palvella TherapeuticsPVLA
$19.8M+50.5%
PTH
Pelthos TherapeuticsPTHS
$5M+300%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$121.36M-1.0%
ESP
ESPRESPR
$72.6M+1.0%
PTH
Pelthos TherapeuticsPTHS
13%
PTH
Pelthos TherapeuticsPTHS
$156K

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept qure:LiabilityFromRoyaltyFinancingAgreementNonCurrent.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemJune 30, 2026December 31, 2025
Total current liabilities83,34562,919
Non-current liabilities
Long-term debt50,14749,699
Liability from royalty financing agreement489,333473,199
Operating lease liabilities, net of current portion9,6969,832
Contingent consideration18,11318,736
Deferred tax liability, net7,7267,967
Other non-current liabilities, net of current portion2,6933,655

Item 1.Financial Statements

FAQ

What is uniQure's liability from royalty financing agreement non current?
uniQure (QURE) reported liability from royalty financing agreement non current of $489.33M in Q2 2026.
How has uniQure's liability from royalty financing agreement non current changed year-over-year?
uniQure's liability from royalty financing agreement non current increased by 7.5% year-over-year, from $455.26M to $489.33M.
What is the long-term trend for uniQure's liability from royalty financing agreement non current?
Over 2 years (2023 to 2025), uniQure's liability from royalty financing agreement non current has grown at a 9.6% compound annual growth rate (CAGR), from $394.24M to $473.2M.
What does liability from royalty financing agreement non current mean?
This reflects the long-term portion of obligations arising from financing arrangements where the company receives upfront capital in exchange for future royalty payments on product sales. It represents a form of non-dilutive financing that creates a long-term claim against future revenue streams. Investors monitor this to evaluate the company's leverage and the impact of future royalty obligations on long-term profitability.

Ask your AI about uniQure's liability from royalty financing agreement non current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude